Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference
BOSTON , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference , including a fireside chat at 8:40 a.m. ET on Tuesday, November 16, 2021 , followed by
View HTML
Toggle Summary Radius Health, Inc.: Third Quarter 2021 Results
TYMLOS ® Q3, 2021 net revenue: $57 million , +13% vs. Q3, 2020 Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020 Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included elacestrant license revenue ATOM Pivotal Study evaluating abaloparatide-SC for use in males
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
BOSTON , Oct. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday, Oct. 20 , by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346) 406-0961 for
View HTML
Toggle Summary Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
Study met both primary endpoints in patients with ER+/HER2- advanced or mBC Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC Elacestrant extended PFS in the overall population and the
View HTML
Toggle Summary Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value
View HTML
Toggle Summary TYMLOS Label and Business Update
TYMLOS® label: significant update to the Mechanism of Action (MOA) section Label change aligns with strategic focus on postmenopausal women at high risk of fracture Danielle Holtschlag joins as Head of Sales, bringing 20 years of experience to the team Added ~3,000 new TYMLOS patients throughout
View HTML
Toggle Summary Radius Health, Inc.: Second Quarter and Year-to-Date Results
Repositioned the Company to create meaningful P+L operating leverage Dramatic improvement in Adj. EBITDA performance: ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020 FY 2021 guidance: reiterate Adj. EBITDA of $10 million while reducing TYMLOS revenue from $250 to $240 million TYMLOS Q2, 2021
View HTML
Toggle Summary Radius Health Business Update
Added 5,000+ new TYMLOS patients in Q2, 2021, up 40+% vs. Q2, 2020 and 3% vs. Q1, 2021 ATOM and wearABLe abaloparatide Phase 3 trial readouts remain on track for 2H, 2021 EU abaloparatide regulatory resubmission remains on schedule for Q4, 2021 Prader-Willi Syndrome (PWS) pivotal Phase 2/3 study to
View HTML
Toggle Summary CORRECTION: Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011 505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studies Based on results, a single well controlled study could serve as the basis for marketing approval RAD011 had previously
View HTML
Toggle Summary Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021
BOSTON , July 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m.
View HTML